Top Story

Novartis confirms 5-year efficacy for Cosentyx for psoriasis

July 18, 2017

Novartis has reported positive 5-year efficacy and safety results for Cosentyx from a phase 3 long-term extension study in patients with moderate-to-severe plaque psoriasis.

Data from the study will be presented at a medical congress in the second half of 2017, according to a news release.

Breaking News

FDA approves Tremfya for psoriasis

July 13, 2017
Janssen Biotech announced that the FDA has approved Tremfya for treating adults with moderate-to-severe psoriasis who are candidates for systemic therapy or…
In the Journals

Nail findings distinguish between psoriasis, psoriatic arthritis

June 30, 2017
Nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis, with transverse grooves being a significant factor, according…

Biosimilar to Enbrel approved in Europe

June 27, 2017
Erelzi, a biosimilar to Enbrel, has been approved by the European Commission for all indications of the reference product, according to a company press release…
More Headlines »

The Patient with Osteoarthritis

No commercial support for this activity.

Osteoarthritis (OA) is a chronic, progressive, multifactorial, and life-long disease characterized by degenerative and…
More »
GI Bookshelf

Chapter 5: Dysplasia And Colorectal Cancer

From Clinical Challenges and Complications of IBD
More »
Resource Centers
American Association of Nurse Practitioners National Conference

American Association of Nurse Practitioners National Conference

Meeting News Coverage

VIDEO: Silverman discusses immunology links between cancer treatments and rheumatic diseases

March 15, 2016
More »